(a) ANOVA classification of medulloblastoma enhancers.
(b) Distribution of differentially regulated enhancers among medulloblastoma enhancer classes.
(c) K-means clustering of differentially regulated medulloblastoma enhancers (n=20,406).
(d) Proportion of enhancer/gene assignments to N enhancers.
(e) Proportion of enhancer/gene assignments to N genes.
(f) WNT-specific enhancer activity (rpm/bp) and expression (log2 RPKM, n=140) of ALK. Error bars represent standard deviation (s.d.) of the mean.
(g) Immunohistochemical validation of ALK expression in WNT medulloblastoma patients (n=49).